# PeptideScanner evidence objects: Elamipretide

Every published version of the records placed with Elamipretide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/elamipretide.json. Selected public evidence only; not medical advice.

- Objects: 52
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct02693119-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT02693119

> PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct02693119-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02693119-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct02693119-elamipretide-v1
- Content SHA-256: `d9e1e1ffb6216fbb4f12ebb29888678bfd691ed38e08fc2516362a1f0e7779d1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02693119 ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

### Sources

<a id="source-ctg-observation-nct02693119-2021-11-30-e6845fd49543"></a>
- **ClinicalTrials.gov record NCT02693119 · retained source version 2021-11-30:e6845fd4954350c08ae8b4d48e1bf0b16fc5add78a67eb673d75cbdee4d7e2bb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02693119) (`ctg-observation-nct02693119-2021-11-30-e6845fd49543`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02693119." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct02693119-elamipretide-v1 SHA-256: d9e1e1ffb6216fbb4f12ebb29888678bfd691ed38e08fc2516362a1f0e7779d1.

---

<a id="clinicaltrials-gov-nct02788747-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT02788747

> PeptideScanner retained ClinicalTrials.gov record NCT02788747 at 2026-07-30T20:27:50.521Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct02788747-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-05-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02788747-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct02788747-elamipretide-v1
- Content SHA-256: `61a7379b25a722a677e8c69a0bc7ffc8b14fd1aa313ca709658fe69f946c67bb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02788747 ([`ctg-observation-nct02788747-2020-05-14-577814da7461`](#source-ctg-observation-nct02788747-2020-05-14-577814da7461))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02788747 at 2026-07-30T20:27:50.521Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct02788747-2020-05-14-577814da7461`](#source-ctg-observation-nct02788747-2020-05-14-577814da7461))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02788747 at 2026-07-30T20:27:50.521Z. Its registry update date was 2020-05-14, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct02788747-2020-05-14-577814da7461`](#source-ctg-observation-nct02788747-2020-05-14-577814da7461))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02788747-2020-05-14-577814da7461`](#source-ctg-observation-nct02788747-2020-05-14-577814da7461))

### Sources

<a id="source-ctg-observation-nct02788747-2020-05-14-577814da7461"></a>
- **ClinicalTrials.gov record NCT02788747 · retained source version 2020-05-14:577814da746181fb420734bd9dded60ebd817304603836cedeb7a188cd18a78a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02788747) (`ctg-observation-nct02788747-2020-05-14-577814da7461`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02788747." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct02788747-elamipretide-v1 SHA-256: 61a7379b25a722a677e8c69a0bc7ffc8b14fd1aa313ca709658fe69f946c67bb.

---

<a id="clinicaltrials-gov-nct03098797-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT03098797

> PeptideScanner retained ClinicalTrials.gov record NCT03098797 at 2026-07-30T18:46:20.414Z. Its registry update date was 2024-04-16, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct03098797-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03098797-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct03098797-elamipretide-v1
- Content SHA-256: `a3f8a03feb2080f9cbbcaaab4690ea393488a4b4646c061420bc5f160bb96b64`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03098797 ([`ctg-observation-nct03098797-2024-04-16-68b705b7aa5a`](#source-ctg-observation-nct03098797-2024-04-16-68b705b7aa5a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03098797 at 2026-07-30T18:46:20.414Z. Its registry update date was 2024-04-16, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct03098797-2024-04-16-68b705b7aa5a`](#source-ctg-observation-nct03098797-2024-04-16-68b705b7aa5a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03098797 at 2026-07-30T18:46:20.414Z. Its registry update date was 2024-04-16, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct03098797-2024-04-16-68b705b7aa5a`](#source-ctg-observation-nct03098797-2024-04-16-68b705b7aa5a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03098797-2024-04-16-68b705b7aa5a`](#source-ctg-observation-nct03098797-2024-04-16-68b705b7aa5a))

### Sources

<a id="source-ctg-observation-nct03098797-2024-04-16-68b705b7aa5a"></a>
- **ClinicalTrials.gov record NCT03098797 · retained source version 2024-04-16:68b705b7aa5a4fc2fb14c5aa69dfa3ef98739b12e5253745fe4b38bd5d408991** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03098797) (`ctg-observation-nct03098797-2024-04-16-68b705b7aa5a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03098797." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct03098797-elamipretide-v1 SHA-256: a3f8a03feb2080f9cbbcaaab4690ea393488a4b4646c061420bc5f160bb96b64.

---

<a id="clinicaltrials-gov-nct03891875-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT03891875

> PeptideScanner retained ClinicalTrials.gov record NCT03891875 at 2026-07-30T18:42:56.626Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct03891875-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-07-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03891875-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct03891875-elamipretide-v1
- Content SHA-256: `afc48a599464b0dbef56e7124bcdc78e8473ebba5cd73a4758306b15716fd07d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03891875 ([`ctg-observation-nct03891875-2024-07-12-a15d2d662536`](#source-ctg-observation-nct03891875-2024-07-12-a15d2d662536))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03891875 at 2026-07-30T18:42:56.626Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct03891875-2024-07-12-a15d2d662536`](#source-ctg-observation-nct03891875-2024-07-12-a15d2d662536))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03891875 at 2026-07-30T18:42:56.626Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct03891875-2024-07-12-a15d2d662536`](#source-ctg-observation-nct03891875-2024-07-12-a15d2d662536))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03891875-2024-07-12-a15d2d662536`](#source-ctg-observation-nct03891875-2024-07-12-a15d2d662536))

### Sources

<a id="source-ctg-observation-nct03891875-2024-07-12-a15d2d662536"></a>
- **ClinicalTrials.gov record NCT03891875 · retained source version 2024-07-12:a15d2d662536c59e9f78ed371efc5bf11adc4e629f58b1be04fbf605ad1110a6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03891875) (`ctg-observation-nct03891875-2024-07-12-a15d2d662536`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03891875." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct03891875-elamipretide-v1 SHA-256: afc48a599464b0dbef56e7124bcdc78e8473ebba5cd73a4758306b15716fd07d.

---

<a id="clinicaltrials-gov-nct05162768-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT05162768

> PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct05162768-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05162768-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct05162768-elamipretide-v1
- Content SHA-256: `fb510f913859dbd8fcd26c366ace1e0ac6b0042adb57590187c11db000a05211`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05162768 ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05162768 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`](#source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd))

### Sources

<a id="source-ctg-observation-nct05162768-2025-10-24-7e45e33488fd"></a>
- **ClinicalTrials.gov record NCT05162768 · retained source version 2025-10-24:7e45e33488fdf229c542f8cf1d0fd1a6e6c1a5f43c04d1eb153e8ada606be685** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05162768) (`ctg-observation-nct05162768-2025-10-24-7e45e33488fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05162768." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct05162768-elamipretide-v1 SHA-256: fb510f913859dbd8fcd26c366ace1e0ac6b0042adb57590187c11db000a05211.

---

<a id="clinicaltrials-gov-nct05168774-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT05168774

> PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct05168774-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05168774-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct05168774-elamipretide-v1
- Content SHA-256: `d2024bf4b6b0ffad0a7706addcb2c946c2b16514d01105000524016728cf164f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05168774 ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05168774 at 2026-07-30T18:18:33.506Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05168774-2025-12-12-b710dca893fb`](#source-ctg-observation-nct05168774-2025-12-12-b710dca893fb))

### Sources

<a id="source-ctg-observation-nct05168774-2025-12-12-b710dca893fb"></a>
- **ClinicalTrials.gov record NCT05168774 · retained source version 2025-12-12:b710dca893fb6d67975a19f6658d9aa6bee1ff37bd95c383b5015319903d4c0e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05168774) (`ctg-observation-nct05168774-2025-12-12-b710dca893fb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05168774." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct05168774-elamipretide-v1 SHA-256: d2024bf4b6b0ffad0a7706addcb2c946c2b16514d01105000524016728cf164f.

---

<a id="clinicaltrials-gov-nct06373731-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT06373731

> PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct06373731-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06373731-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct06373731-elamipretide-v1
- Content SHA-256: `b507c489420ca4defc65866b9bd15ac57df508a7761d9abc167e438e3df61d5c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06373731 ([`ctg-observation-nct06373731-2026-05-20-a600f5a19971`](#source-ctg-observation-nct06373731-2026-05-20-a600f5a19971))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct06373731-2026-05-20-a600f5a19971`](#source-ctg-observation-nct06373731-2026-05-20-a600f5a19971))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06373731 at 2026-07-30T16:19:36.914Z. Its registry update date was 2026-05-20, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct06373731-2026-05-20-a600f5a19971`](#source-ctg-observation-nct06373731-2026-05-20-a600f5a19971))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06373731-2026-05-20-a600f5a19971`](#source-ctg-observation-nct06373731-2026-05-20-a600f5a19971))

### Sources

<a id="source-ctg-observation-nct06373731-2026-05-20-a600f5a19971"></a>
- **ClinicalTrials.gov record NCT06373731 · retained source version 2026-05-20:a600f5a1997151245694bb91d29e9513fe32f6574aad0a628fa2bde0f6d61d73** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06373731) (`ctg-observation-nct06373731-2026-05-20-a600f5a19971`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06373731." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct06373731-elamipretide-v1 SHA-256: b507c489420ca4defc65866b9bd15ac57df508a7761d9abc167e438e3df61d5c.

---

<a id="clinicaltrials-gov-nct07531251-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT07531251

> PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct07531251-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-13
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07531251-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct07531251-elamipretide-v1
- Content SHA-256: `1b6f79003bede7a3f8e2d35af34687f98f0158511fb794a119343d44ced1262c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07531251 ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f))

### Sources

<a id="source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f"></a>
- **ClinicalTrials.gov record NCT07531251 · retained source version 2026-07-13:a3abd3798f6f0dcd17555c9da0b3347859e9f47c7f7f691e6cc9870654fd9f5a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07531251) (`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07531251." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct07531251-elamipretide-v1 SHA-256: 1b6f79003bede7a3f8e2d35af34687f98f0158511fb794a119343d44ced1262c.

---

<a id="clinicaltrials-gov-nct07531251-elamipretide-v2"></a>

## ClinicalTrials.gov record NCT07531251

> PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct07531251-elamipretide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07531251-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct07531251-elamipretide-v2
- Content SHA-256: `46563f3805b5e5be9a656a53fe39ccd6b8d2f022507b47289d04d56d8bb433af`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07531251 ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2))

### Sources

<a id="source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2"></a>
- **ClinicalTrials.gov record NCT07531251 · retained source version 2026-11-09:8d985a85fd7cea4c1942696d014f6e48a6dd6fde4500944df40f503eef786fd1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07531251) (`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2`)

### Correction lineage

updated on 2026-11-15: ClinicalTrials.gov posted a newer version of NCT07531251, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2`](#source-ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07531251." Version 2, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct07531251-elamipretide-v2 SHA-256: 46563f3805b5e5be9a656a53fe39ccd6b8d2f022507b47289d04d56d8bb433af.

---

<a id="clinicaltrials-gov-nct07927972-elamipretide-v1"></a>

## ClinicalTrials.gov record NCT07927972

> PeptideScanner retained ClinicalTrials.gov record NCT07927972 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct07927972-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07927972-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct07927972-elamipretide-v1
- Content SHA-256: `acbe421c2d29874b4e811cd7ac6428bc66bc5f9536fa1521b405fb2802afff3e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07927972 ([`ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0`](#source-ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07927972 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0`](#source-ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07927972 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0`](#source-ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0`](#source-ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0))

### Sources

<a id="source-ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0"></a>
- **ClinicalTrials.gov record NCT07927972 · retained source version 2026-11-10:5e3fdfdaf1e06827947b8a289d1f39855deb198d766062e99d7a68dd64d583bb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07927972) (`ctg-observation-nct07927972-2026-11-10-5e3fdfdaf1e0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07927972." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#clinicaltrials-gov-nct07927972-elamipretide-v1 SHA-256: acbe421c2d29874b4e811cd7ac6428bc66bc5f9536fa1521b405fb2802afff3e.

---

<a id="elamipretide-barth-syndrome-study-updated-v1"></a>

## Elamipretide Barth syndrome study record updated

> ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc.

- Evidence object: `story:elamipretide-barth-syndrome-study-updated:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-13
- Source checked: 2026-07-22
- Published by PeptideScanner: 2026-07-22
- Story landing page: https://peptidescanner.com/stories/elamipretide-barth-syndrome-study-updated/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#elamipretide-barth-syndrome-study-updated-v1
- Content SHA-256: `021258f5072338843f8be8aa117acec7f447f8f9d8aa0d7a83c4644f3baa31be`

### Claims and source pins

#### Headline

Elamipretide Barth syndrome study record updated ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

#### Summary

ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc. ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

#### Paragraph 1

ClinicalTrials.gov lists the NCT07531251 record under Stealth BioTherapeutics Inc. Its overall recruitment status was shown as recruiting when PeptideScanner reviewed the record. ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

#### Paragraph 2

The registry shows 2026-07-13 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome. ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

### Sources

<a id="source-ctg-nct07531251-v4"></a>
- **4TAZPower: Elamipretide in Participants With Barth Syndrome · record history version 4 · last update posted 2026-07-13** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07531251?a=4&tab=history) (`ctg-nct07531251-v4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Elamipretide Barth syndrome study record updated." Version 1, published 2026-07-22. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#elamipretide-barth-syndrome-study-updated-v1 SHA-256: 021258f5072338843f8be8aa117acec7f447f8f9d8aa0d7a83c4644f3baa31be.

---

<a id="federal-register-2024-20062-v1"></a>

## Federal Register notice 2024-20062

> The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.

- Evidence object: `story:federal-register-2024-20062:v1`
- Evidence domain: Regulatory
- Date in source: 2024-09-06
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-20062/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#federal-register-2024-20062-v1
- Content SHA-256: `b324b0f651905b7a54ffa0a58b8341e68150c02dcb534531e7cf3238b82e462a`

### Claims and source pins

#### Headline

Federal Register notice 2024-20062 ([`federal-register-2024-20062-66035b025ae4`](#source-federal-register-2024-20062-66035b025ae4))

#### Summary

The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide. ([`federal-register-2024-20062-66035b025ae4`](#source-federal-register-2024-20062-66035b025ae4))

#### Paragraph 1

The Federal Register published notice 2024-20062, attributed to FDA and its parent HHS department, on 2024-09-06. Its official title is “Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection,” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide. ([`federal-register-2024-20062-66035b025ae4`](#source-federal-register-2024-20062-66035b025ae4))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-20062-66035b025ae4`](#source-federal-register-2024-20062-66035b025ae4))

### Sources

<a id="source-federal-register-2024-20062-66035b025ae4"></a>
- **Federal Register notice 2024-20062 · published 2024-09-06 · Cardiovascular and Renal Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application 215244 for Elamipretide Hydrochloride Injection** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20062.pdf) (`federal-register-2024-20062-66035b025ae4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-20062." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#federal-register-2024-20062-v1 SHA-256: b324b0f651905b7a54ffa0a58b8341e68150c02dcb534531e7cf3238b82e462a.

---

<a id="federal-register-2025-23409-v1"></a>

## Federal Register notice 2025-23409

> The Federal Register published notice 2025-23409, attributed to FDA and its parent HHS department, on 2025-12-19. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide),” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide.

- Evidence object: `story:federal-register-2025-23409:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-19
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-23409/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#federal-register-2025-23409-v1
- Content SHA-256: `2c2a3ffc57f320c54399c894f2b19f7bf79f4bff71f2f10fb2acfff921ad7c59`

### Claims and source pins

#### Headline

Federal Register notice 2025-23409 ([`federal-register-2025-23409-a1a99e53ad16`](#source-federal-register-2025-23409-a1a99e53ad16))

#### Summary

The Federal Register published notice 2025-23409, attributed to FDA and its parent HHS department, on 2025-12-19. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide),” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide. ([`federal-register-2025-23409-a1a99e53ad16`](#source-federal-register-2025-23409-a1a99e53ad16))

#### Paragraph 1

The Federal Register published notice 2025-23409, attributed to FDA and its parent HHS department, on 2025-12-19. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide),” and PeptideScanner's exact reviewed identity mapping connects the document to Elamipretide. ([`federal-register-2025-23409-a1a99e53ad16`](#source-federal-register-2025-23409-a1a99e53ad16))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-23409-a1a99e53ad16`](#source-federal-register-2025-23409-a1a99e53ad16))

### Sources

<a id="source-federal-register-2025-23409-a1a99e53ad16"></a>
- **Federal Register notice 2025-23409 · published 2025-12-19 · Issuance of Priority Review Voucher; Rare Pediatric Disease Product; FORZINITY (Elamipretide)** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-12-19/pdf/2025-23409.pdf) (`federal-register-2025-23409-a1a99e53ad16`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-23409." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#federal-register-2025-23409-v1 SHA-256: 2c2a3ffc57f320c54399c894f2b19f7bf79f4bff71f2f10fb2acfff921ad7c59.

---

<a id="pubmed-pmid-17151329-elamipretide-v1"></a>

## PubMed record PMID 17151329

> PeptideScanner retained PubMed bibliographic metadata for PMID 17151329 at 2026-07-30T21:55:37.962Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2006-12-08. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-17151329-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2014-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17151329-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-17151329-elamipretide-v1
- Content SHA-256: `b3eff0e3db7f0f57ca4305356893c56d23b339d959d0d22a885e645efc0e8ab9`

### Claims and source pins

#### Headline

PubMed record PMID 17151329 ([`pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee`](#source-pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 17151329 at 2026-07-30T21:55:37.962Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2006-12-08. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee`](#source-pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 17151329 at 2026-07-30T21:55:37.962Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2006-12-08. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee`](#source-pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee`](#source-pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee))

### Sources

<a id="source-pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee"></a>
- **PubMed record PMID 17151329 · retained source version 1:2014-11-20:current:0e07ecda3dee79b3c6b0247441d8d09d54bab2853837a27dc5008755cb263ecb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17151329/) (`pubmed-observation-pmid-17151329-2014-11-20-0e07ecda3dee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 17151329." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-17151329-elamipretide-v1 SHA-256: b3eff0e3db7f0f57ca4305356893c56d23b339d959d0d22a885e645efc0e8ab9.

---

<a id="pubmed-pmid-21697135-elamipretide-v1"></a>

## PubMed record PMID 21697135

> PeptideScanner retained PubMed bibliographic metadata for PMID 21697135 at 2026-07-30T21:57:00.496Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 2011-06-24. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-21697135-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21697135-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-21697135-elamipretide-v1
- Content SHA-256: `0797e59fef1fe60ee5ef4da892cd54b75b0f87bce35ef1c71cac9ad56aceab9d`

### Claims and source pins

#### Headline

PubMed record PMID 21697135 ([`pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67`](#source-pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 21697135 at 2026-07-30T21:57:00.496Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 2011-06-24. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67`](#source-pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 21697135 at 2026-07-30T21:57:00.496Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 2011-06-24. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67`](#source-pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67`](#source-pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67))

### Sources

<a id="source-pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67"></a>
- **PubMed record PMID 21697135 · retained source version 1:2013-11-21:current:83d5064c9e67c5c62f73a9dbefe6dfb82682042eb25a69b10c91e8ed9010e6e8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21697135/) (`pubmed-observation-pmid-21697135-2013-11-21-83d5064c9e67`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 21697135." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-21697135-elamipretide-v1 SHA-256: 0797e59fef1fe60ee5ef4da892cd54b75b0f87bce35ef1c71cac9ad56aceab9d.

---

<a id="pubmed-pmid-23813215-elamipretide-v1"></a>

## The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin.

> PubMed lists PMID 23813215 in Journal of the American Society of Nephrology : JASN as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23813215-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23813215-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-23813215-elamipretide-v1
- Content SHA-256: `9eb0ed2934b6653d3ce5c9ff46d2c0046c537a68eb1e773e0a4852098059a538`

### Claims and source pins

#### Headline

The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. ([`pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b`](#source-pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b))

#### Summary

PubMed lists PMID 23813215 in Journal of the American Society of Nephrology : JASN as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b`](#source-pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b))

#### Paragraph 1

PubMed lists PMID 23813215 in Journal of the American Society of Nephrology : JASN as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b`](#source-pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b`](#source-pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b))

### Sources

<a id="source-pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b"></a>
- **The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. · retained source version 1:2021-10-21:current:7ccc75669b0b8a5c80bbb2e86accc6419d6a48c6d87b1cc40397c80a9bfca71b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23813215/) (`pubmed-observation-pmid-23813215-2021-10-21-7ccc75669b0b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-23813215-elamipretide-v1 SHA-256: 9eb0ed2934b6653d3ce5c9ff46d2c0046c537a68eb1e773e0a4852098059a538.

---

<a id="pubmed-pmid-29951944-elamipretide-v1"></a>

## Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide.

> PubMed lists PMID 29951944 in Cardiovascular drugs and therapy as Journal Article, with publication-date metadata of 2018-08 (month precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29951944-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29951944-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-29951944-elamipretide-v1
- Content SHA-256: `f8b0763a2db5dc858334cf07e004332119bfec9ccd46a3528105bad66cfe8763`

### Claims and source pins

#### Headline

Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide. ([`pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207`](#source-pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207))

#### Summary

PubMed lists PMID 29951944 in Cardiovascular drugs and therapy as Journal Article, with publication-date metadata of 2018-08 (month precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207`](#source-pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207))

#### Paragraph 1

PubMed lists PMID 29951944 in Cardiovascular drugs and therapy as Journal Article, with publication-date metadata of 2018-08 (month precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207`](#source-pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207`](#source-pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207))

### Sources

<a id="source-pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207"></a>
- **Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide. · retained source version 1:2024-03-12:current:73fa9764a20798cd9cbd453bf574f187db4ad0deb543059c5fdfc2319cc759a6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29951944/) (`pubmed-observation-pmid-29951944-2024-03-12-73fa9764a207`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-29951944-elamipretide-v1 SHA-256: f8b0763a2db5dc858334cf07e004332119bfec9ccd46a3528105bad66cfe8763.

---

<a id="pubmed-pmid-32096613-elamipretide-v1"></a>

## A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.

> PubMed lists PMID 32096613 in Journal of cachexia, sarcopenia and muscle as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32096613-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-08-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32096613-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-32096613-elamipretide-v1
- Content SHA-256: `1112808400294b2b297468e4fa026d4c79114ac1ebfb69c80c4913877c3e3fcb`

### Claims and source pins

#### Headline

A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. ([`pubmed-observation-pmid-32096613-2024-08-01-2de27befa715`](#source-pubmed-observation-pmid-32096613-2024-08-01-2de27befa715))

#### Summary

PubMed lists PMID 32096613 in Journal of cachexia, sarcopenia and muscle as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32096613-2024-08-01-2de27befa715`](#source-pubmed-observation-pmid-32096613-2024-08-01-2de27befa715))

#### Paragraph 1

PubMed lists PMID 32096613 in Journal of cachexia, sarcopenia and muscle as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32096613-2024-08-01-2de27befa715`](#source-pubmed-observation-pmid-32096613-2024-08-01-2de27befa715))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32096613-2024-08-01-2de27befa715`](#source-pubmed-observation-pmid-32096613-2024-08-01-2de27befa715))

### Sources

<a id="source-pubmed-observation-pmid-32096613-2024-08-01-2de27befa715"></a>
- **A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. · retained source version 1:2024-08-01:current:2de27befa715b62f9d131c1f5e2925f1252d023bb34e809baa79a7b2c7acb59b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32096613/) (`pubmed-observation-pmid-32096613-2024-08-01-2de27befa715`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-32096613-elamipretide-v1 SHA-256: 1112808400294b2b297468e4fa026d4c79114ac1ebfb69c80c4913877c3e3fcb.

---

<a id="pubmed-pmid-32554501-elamipretide-v1"></a>

## Mitochondrial protein interaction landscape of SS-31.

> PubMed lists PMID 32554501 in Proceedings of the National Academy of Sciences of the United States of America as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32554501-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32554501-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-32554501-elamipretide-v1
- Content SHA-256: `dea6350a4af427ddf43a565d6ba8b0cd5c82f9a0e3845e7d5db783501c86a4d1`

### Claims and source pins

#### Headline

Mitochondrial protein interaction landscape of SS-31. ([`pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68`](#source-pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68))

#### Summary

PubMed lists PMID 32554501 in Proceedings of the National Academy of Sciences of the United States of America as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68`](#source-pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68))

#### Paragraph 1

PubMed lists PMID 32554501 in Proceedings of the National Academy of Sciences of the United States of America as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-06-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68`](#source-pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68`](#source-pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68))

### Sources

<a id="source-pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68"></a>
- **Mitochondrial protein interaction landscape of SS-31. · retained source version 1:2024-03-30:current:b3ffbe4d2b68785b34396746632608b1d11128d5b301312fd7a79a15005eb7df** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32554501/) (`pubmed-observation-pmid-32554501-2024-03-30-b3ffbe4d2b68`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Mitochondrial protein interaction landscape of SS-31." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-32554501-elamipretide-v1 SHA-256: dea6350a4af427ddf43a565d6ba8b0cd5c82f9a0e3845e7d5db783501c86a4d1.

---

<a id="pubmed-pmid-34623544-elamipretide-v1"></a>

## Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.

> PubMed lists PMID 34623544 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-10-08 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34623544-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34623544-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-34623544-elamipretide-v1
- Content SHA-256: `e8b2093f3bb8f8ed3edd07d68e672069eec279307f2aef38b20dc1b31b1c1d7d`

### Claims and source pins

#### Headline

Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. ([`pubmed-observation-pmid-34623544-2025-07-28-067e0526282b`](#source-pubmed-observation-pmid-34623544-2025-07-28-067e0526282b))

#### Summary

PubMed lists PMID 34623544 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-10-08 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34623544-2025-07-28-067e0526282b`](#source-pubmed-observation-pmid-34623544-2025-07-28-067e0526282b))

#### Paragraph 1

PubMed lists PMID 34623544 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-10-08 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34623544-2025-07-28-067e0526282b`](#source-pubmed-observation-pmid-34623544-2025-07-28-067e0526282b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34623544-2025-07-28-067e0526282b`](#source-pubmed-observation-pmid-34623544-2025-07-28-067e0526282b))

### Sources

<a id="source-pubmed-observation-pmid-34623544-2025-07-28-067e0526282b"></a>
- **Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid. · retained source version 1:2025-07-28:current:067e0526282b47ad3def0faf0a9a390d8b25739774fa6b0553cfaac868cc63e5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34623544/) (`pubmed-observation-pmid-34623544-2025-07-28-067e0526282b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-34623544-elamipretide-v1 SHA-256: e8b2093f3bb8f8ed3edd07d68e672069eec279307f2aef38b20dc1b31b1c1d7d.

---

<a id="pubmed-pmid-35037146-elamipretide-v1"></a>

## Targeting mitochondrial dysfunction with elamipretide.

> PubMed lists PMID 35037146 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-01-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35037146-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-07-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35037146-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-35037146-elamipretide-v1
- Content SHA-256: `dc5dfb11d9fb75ad99c21d55d213b0217b7a864637ab60907047164abccdb798`

### Claims and source pins

#### Headline

Targeting mitochondrial dysfunction with elamipretide. ([`pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e`](#source-pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e))

#### Summary

PubMed lists PMID 35037146 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-01-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e`](#source-pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e))

#### Paragraph 1

PubMed lists PMID 35037146 in Heart failure reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-01-17 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e`](#source-pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e`](#source-pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e))

### Sources

<a id="source-pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e"></a>
- **Targeting mitochondrial dysfunction with elamipretide. · retained source version 1:2025-07-28:current:d0cd8ca6d86eb3d7a9c74d20b8872ca6cc919ff747b82d0e549548f5293b20aa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35037146/) (`pubmed-observation-pmid-35037146-2025-07-28-d0cd8ca6d86e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Targeting mitochondrial dysfunction with elamipretide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-35037146-elamipretide-v1 SHA-256: dc5dfb11d9fb75ad99c21d55d213b0217b7a864637ab60907047164abccdb798.

---

<a id="pubmed-pmid-35611788-elamipretide-v1"></a>

## PubMed record PMID 35611788

> PeptideScanner retained PubMed bibliographic metadata for PMID 35611788 at 2026-08-10T18:13:32.311Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2022-05-25. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-35611788-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35611788-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-35611788-elamipretide-v1
- Content SHA-256: `4f3c8f8af31e4cb20fc6dc2022e83b1e4935c1a146d82803496216d30b927454`

### Claims and source pins

#### Headline

PubMed record PMID 35611788 ([`pubmed-observation-pmid-35611788-2026-07-26-460a542909e3`](#source-pubmed-observation-pmid-35611788-2026-07-26-460a542909e3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 35611788 at 2026-08-10T18:13:32.311Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2022-05-25. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-35611788-2026-07-26-460a542909e3`](#source-pubmed-observation-pmid-35611788-2026-07-26-460a542909e3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 35611788 at 2026-08-10T18:13:32.311Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2022-05-25. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-35611788-2026-07-26-460a542909e3`](#source-pubmed-observation-pmid-35611788-2026-07-26-460a542909e3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35611788-2026-07-26-460a542909e3`](#source-pubmed-observation-pmid-35611788-2026-07-26-460a542909e3))

### Sources

<a id="source-pubmed-observation-pmid-35611788-2026-07-26-460a542909e3"></a>
- **PubMed record PMID 35611788 · retained source version 1:2026-07-26:current:460a542909e3d2e54eb3bfc31e1399ee587272549f5b5b6be46b30a5aa1e002e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35611788/) (`pubmed-observation-pmid-35611788-2026-07-26-460a542909e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 35611788." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-35611788-elamipretide-v1 SHA-256: 4f3c8f8af31e4cb20fc6dc2022e83b1e4935c1a146d82803496216d30b927454.

---

<a id="pubmed-pmid-36636586-elamipretide-v1"></a>

## Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

> PubMed lists PMID 36636586 in JIMD reports as Journal Article, with publication-date metadata of 2022-09-21 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36636586-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-08-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36636586-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-36636586-elamipretide-v1
- Content SHA-256: `b8c14629f2d9fc5d8d4e006417e9c099525b5365e40d0991b5a052ac4c9441a9`

### Claims and source pins

#### Headline

Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases. ([`pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe`](#source-pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe))

#### Summary

PubMed lists PMID 36636586 in JIMD reports as Journal Article, with publication-date metadata of 2022-09-21 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe`](#source-pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe))

#### Paragraph 1

PubMed lists PMID 36636586 in JIMD reports as Journal Article, with publication-date metadata of 2022-09-21 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe`](#source-pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe`](#source-pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe))

### Sources

<a id="source-pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe"></a>
- **Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases. · retained source version 1:2023-08-15:current:e16bd31c7efe85af39f6925d450be2c40995adc030ee26b5f59976caa2b3241f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36636586/) (`pubmed-observation-pmid-36636586-2023-08-15-e16bd31c7efe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-36636586-elamipretide-v1 SHA-256: b8c14629f2d9fc5d8d4e006417e9c099525b5365e40d0991b5a052ac4c9441a9.

---

<a id="pubmed-pmid-36840897-elamipretide-v1"></a>

## Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice.

> PubMed lists PMID 36840897 in GeroScience as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36840897-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-07-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36840897-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-36840897-elamipretide-v1
- Content SHA-256: `8ce2cd9ae342d875865dd71e134334db3f72f73f214aa9cf2da3817b060e24ec`

### Claims and source pins

#### Headline

Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. ([`pubmed-observation-pmid-36840897-2024-07-19-739c298e887e`](#source-pubmed-observation-pmid-36840897-2024-07-19-739c298e887e))

#### Summary

PubMed lists PMID 36840897 in GeroScience as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36840897-2024-07-19-739c298e887e`](#source-pubmed-observation-pmid-36840897-2024-07-19-739c298e887e))

#### Paragraph 1

PubMed lists PMID 36840897 in GeroScience as Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-25 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36840897-2024-07-19-739c298e887e`](#source-pubmed-observation-pmid-36840897-2024-07-19-739c298e887e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36840897-2024-07-19-739c298e887e`](#source-pubmed-observation-pmid-36840897-2024-07-19-739c298e887e))

### Sources

<a id="source-pubmed-observation-pmid-36840897-2024-07-19-739c298e887e"></a>
- **Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice. · retained source version 1:2024-07-19:current:739c298e887e8b689a7e5ffcdd843d60a2a049d3c31a73107a78c1ad3116ede3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36840897/) (`pubmed-observation-pmid-36840897-2024-07-19-739c298e887e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-36840897-elamipretide-v1 SHA-256: 8ce2cd9ae342d875865dd71e134334db3f72f73f214aa9cf2da3817b060e24ec.

---

<a id="pubmed-pmid-37041653-elamipretide-v1"></a>

## Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.

> PubMed lists PMID 37041653 in Orphanet journal of rare diseases as Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37041653-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37041653-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-37041653-elamipretide-v1
- Content SHA-256: `30102fdb2087eef04f8a405fa2552715197acc522c943b6bd9f56c3c8147f52f`

### Claims and source pins

#### Headline

Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. ([`pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6`](#source-pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6))

#### Summary

PubMed lists PMID 37041653 in Orphanet journal of rare diseases as Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6`](#source-pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6))

#### Paragraph 1

PubMed lists PMID 37041653 in Orphanet journal of rare diseases as Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6`](#source-pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6`](#source-pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6))

### Sources

<a id="source-pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6"></a>
- **Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. · retained source version 1:2026-01-27:current:15798e96daf651afc6e9ce13ad2e7b23506fdabcd9f6ecd7335627321a25386a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37041653/) (`pubmed-observation-pmid-37041653-2026-01-27-15798e96daf6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-37041653-elamipretide-v1 SHA-256: 30102fdb2087eef04f8a405fa2552715197acc522c943b6bd9f56c3c8147f52f.

---

<a id="pubmed-pmid-37268435-elamipretide-v1"></a>

## PubMed record PMID 37268435

> PeptideScanner retained PubMed bibliographic metadata for PMID 37268435 at 2026-07-30T16:20:36.524Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-06-02. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-37268435-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37268435-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-37268435-elamipretide-v1
- Content SHA-256: `3dea55a1fa5c96fa46af3feac972be22e6484ab14c7e1af1e21e8d20ca936f56`

### Claims and source pins

#### Headline

PubMed record PMID 37268435 ([`pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689`](#source-pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 37268435 at 2026-07-30T16:20:36.524Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-06-02. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689`](#source-pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 37268435 at 2026-07-30T16:20:36.524Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2023-06-02. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689`](#source-pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689`](#source-pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689))

### Sources

<a id="source-pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689"></a>
- **PubMed record PMID 37268435 · retained source version 1:2026-05-18:current:2eb7fab6f6891c35cdf28c7523873adaea569e0a67558f9e05624a37ec625b74** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37268435/) (`pubmed-observation-pmid-37268435-2026-05-18-2eb7fab6f689`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 37268435." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-37268435-elamipretide-v1 SHA-256: 3dea55a1fa5c96fa46af3feac972be22e6484ab14c7e1af1e21e8d20ca936f56.

---

<a id="pubmed-pmid-37325898-elamipretide-v1"></a>

## Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.

> PubMed lists PMID 37325898 in Future cardiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-16 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37325898-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37325898-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-37325898-elamipretide-v1
- Content SHA-256: `225b34d23d0dd2f72f85753aaeb41ff6541b368556576a528660bc71539469c0`

### Claims and source pins

#### Headline

Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

#### Summary

PubMed lists PMID 37325898 in Future cardiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-16 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

#### Paragraph 1

PubMed lists PMID 37325898 in Future cardiology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-06-16 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`](#source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce))

### Sources

<a id="source-pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce"></a>
- **Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide. · retained source version 1:2026-01-27:current:ef04fef6bbce780c54d2423f0287143002ff5923f9b441943d7d0b72788af6cf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37325898/) (`pubmed-observation-pmid-37325898-2026-01-27-ef04fef6bbce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-37325898-elamipretide-v1 SHA-256: 225b34d23d0dd2f72f85753aaeb41ff6541b368556576a528660bc71539469c0.

---

<a id="pubmed-pmid-38237649-elamipretide-v1"></a>

## PubMed record PMID 38237649

> PeptideScanner retained PubMed bibliographic metadata for PMID 38237649 at 2026-08-10T18:13:32.340Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2024-01-18. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38237649-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38237649-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38237649-elamipretide-v1
- Content SHA-256: `2872d1fbd6a75cb74e905a7c6bb5150530dd966436b2e9b7805f7bfa73cb9e55`

### Claims and source pins

#### Headline

PubMed record PMID 38237649 ([`pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f`](#source-pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38237649 at 2026-08-10T18:13:32.340Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2024-01-18. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f`](#source-pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38237649 at 2026-08-10T18:13:32.340Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2024-01-18. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f`](#source-pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f`](#source-pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f))

### Sources

<a id="source-pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f"></a>
- **PubMed record PMID 38237649 · retained source version 1:2026-07-09:current:fab2e6c8e72f872f5393809c313857c7e6631fa4df3f821715befc2f3e743124** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38237649/) (`pubmed-observation-pmid-38237649-2026-07-09-fab2e6c8e72f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38237649." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38237649-elamipretide-v1 SHA-256: 2872d1fbd6a75cb74e905a7c6bb5150530dd966436b2e9b7805f7bfa73cb9e55.

---

<a id="pubmed-pmid-38602181-elamipretide-v1"></a>

## PubMed record PMID 38602181

> PeptideScanner retained PubMed bibliographic metadata for PMID 38602181 at 2026-07-30T16:11:44.832Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2024-04-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38602181-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38602181-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38602181-elamipretide-v1
- Content SHA-256: `d6c6adba78abdcb506fa0756b554e7009ab7aa1bc574dc8578867977a202e528`

### Claims and source pins

#### Headline

PubMed record PMID 38602181 ([`pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9`](#source-pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38602181 at 2026-07-30T16:11:44.832Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2024-04-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9`](#source-pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38602181 at 2026-07-30T16:11:44.832Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2024-04-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9`](#source-pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9`](#source-pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9))

### Sources

<a id="source-pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9"></a>
- **PubMed record PMID 38602181 · retained source version 1:2026-07-01:current:0e9ddaa00ad94fcbf2849c7c397a731e9013a703940188116b30e5124bb76b61** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38602181/) (`pubmed-observation-pmid-38602181-2026-07-01-0e9ddaa00ad9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38602181." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38602181-elamipretide-v1 SHA-256: d6c6adba78abdcb506fa0756b554e7009ab7aa1bc574dc8578867977a202e528.

---

<a id="pubmed-pmid-38688894-elamipretide-v1"></a>

## PubMed record PMID 38688894

> PeptideScanner retained PubMed bibliographic metadata for PMID 38688894 at 2026-07-30T16:14:06.935Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38688894-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38688894-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38688894-elamipretide-v1
- Content SHA-256: `43dd9eb5062ffb5191e2f3ac1ef625fdbf3404676a8c7f21ae3dbed6c62e0db4`

### Claims and source pins

#### Headline

PubMed record PMID 38688894 ([`pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0`](#source-pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38688894 at 2026-07-30T16:14:06.935Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0`](#source-pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38688894 at 2026-07-30T16:14:06.935Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0`](#source-pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0`](#source-pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0))

### Sources

<a id="source-pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0"></a>
- **PubMed record PMID 38688894 · retained source version 1:2026-06-27:current:7e67c323e1a00bfff239e54e3860cd590d614c5d9ce47b29a64971c61df2535d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38688894/) (`pubmed-observation-pmid-38688894-2026-06-27-7e67c323e1a0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38688894." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38688894-elamipretide-v1 SHA-256: 43dd9eb5062ffb5191e2f3ac1ef625fdbf3404676a8c7f21ae3dbed6c62e0db4.

---

<a id="pubmed-pmid-38990651-elamipretide-v1"></a>

## PubMed record PMID 38990651

> PeptideScanner retained PubMed bibliographic metadata for PMID 38990651 at 2026-07-30T16:14:08.785Z. PubMed recorded a metadata revision date of 2026-06-01 and an Entrez history date of 2024-07-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38990651-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38990651-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38990651-elamipretide-v1
- Content SHA-256: `e7281fb57a364b2424939b98167635b17d4dd84f78515f14376d7cf37970bb50`

### Claims and source pins

#### Headline

PubMed record PMID 38990651 ([`pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2`](#source-pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38990651 at 2026-07-30T16:14:08.785Z. PubMed recorded a metadata revision date of 2026-06-01 and an Entrez history date of 2024-07-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2`](#source-pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38990651 at 2026-07-30T16:14:08.785Z. PubMed recorded a metadata revision date of 2026-06-01 and an Entrez history date of 2024-07-11. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2`](#source-pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2`](#source-pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2))

### Sources

<a id="source-pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2"></a>
- **PubMed record PMID 38990651 · retained source version 1:2026-06-01:current:867aba6bd5c2eb9ade10ae8a03581da124d43af9ef95dcc81704db3b117fda42** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38990651/) (`pubmed-observation-pmid-38990651-2026-06-01-867aba6bd5c2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38990651." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-38990651-elamipretide-v1 SHA-256: e7281fb57a364b2424939b98167635b17d4dd84f78515f14376d7cf37970bb50.

---

<a id="pubmed-pmid-39574155-elamipretide-v1"></a>

## PubMed record PMID 39574155

> PeptideScanner retained PubMed bibliographic metadata for PMID 39574155 at 2026-07-30T16:20:39.074Z. PubMed recorded a metadata revision date of 2026-05-19 and an Entrez history date of 2024-11-22. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39574155-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39574155-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39574155-elamipretide-v1
- Content SHA-256: `2988e03d6b6758a8f9193192d954a3661e1b060060d1aa94457e544df7e885e0`

### Claims and source pins

#### Headline

PubMed record PMID 39574155 ([`pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1`](#source-pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39574155 at 2026-07-30T16:20:39.074Z. PubMed recorded a metadata revision date of 2026-05-19 and an Entrez history date of 2024-11-22. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1`](#source-pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39574155 at 2026-07-30T16:20:39.074Z. PubMed recorded a metadata revision date of 2026-05-19 and an Entrez history date of 2024-11-22. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1`](#source-pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1`](#source-pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1))

### Sources

<a id="source-pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1"></a>
- **PubMed record PMID 39574155 · retained source version 1:2026-05-19:current:2bf7c19684e1eb8e7b69c2cdff4a2f864eeea5af32283208eb16c3d9a3ee8f4d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39574155/) (`pubmed-observation-pmid-39574155-2026-05-19-2bf7c19684e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39574155." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39574155-elamipretide-v1 SHA-256: 2988e03d6b6758a8f9193192d954a3661e1b060060d1aa94457e544df7e885e0.

---

<a id="pubmed-pmid-39605874-elamipretide-v1"></a>

## PubMed record PMID 39605874

> PeptideScanner retained PubMed bibliographic metadata for PMID 39605874 at 2026-07-30T16:20:39.082Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2024-11-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39605874-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39605874-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39605874-elamipretide-v1
- Content SHA-256: `a79fb30f32c8937fda8f898dea7898c167b503d682af255db012b68f3bed5881`

### Claims and source pins

#### Headline

PubMed record PMID 39605874 ([`pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4`](#source-pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39605874 at 2026-07-30T16:20:39.082Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2024-11-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4`](#source-pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39605874 at 2026-07-30T16:20:39.082Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2024-11-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4`](#source-pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4`](#source-pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4))

### Sources

<a id="source-pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4"></a>
- **PubMed record PMID 39605874 · retained source version 1:2026-05-18:current:94ea9b0f8ef4a93bad2b4098d7765591c086349f385ec3764f714176e67bdb52** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39605874/) (`pubmed-observation-pmid-39605874-2026-05-18-94ea9b0f8ef4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39605874." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39605874-elamipretide-v1 SHA-256: a79fb30f32c8937fda8f898dea7898c167b503d682af255db012b68f3bed5881.

---

<a id="pubmed-pmid-39669625-elamipretide-v1"></a>

## Expanded-access use of elamipretide in a critically ill patient with Barth syndrome.

> PubMed lists PMID 39669625 in Genetics in medicine open as Journal Article, with publication-date metadata of 2024-06-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39669625-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-12-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39669625-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39669625-elamipretide-v1
- Content SHA-256: `bd3bbf6ea51fd040948b715c0db196993936135c0ada1040d9f634362c6a56d7`

### Claims and source pins

#### Headline

Expanded-access use of elamipretide in a critically ill patient with Barth syndrome. ([`pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2`](#source-pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2))

#### Summary

PubMed lists PMID 39669625 in Genetics in medicine open as Journal Article, with publication-date metadata of 2024-06-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2`](#source-pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2))

#### Paragraph 1

PubMed lists PMID 39669625 in Genetics in medicine open as Journal Article, with publication-date metadata of 2024-06-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2`](#source-pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2`](#source-pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2))

### Sources

<a id="source-pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2"></a>
- **Expanded-access use of elamipretide in a critically ill patient with Barth syndrome. · retained source version 1:2024-12-14:current:d054d25c2ef27ac3ecdfea92d93206bee8987c744ddb04cdd151bf6861e0706f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39669625/) (`pubmed-observation-pmid-39669625-2024-12-14-d054d25c2ef2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Expanded-access use of elamipretide in a critically ill patient with Barth syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39669625-elamipretide-v1 SHA-256: bd3bbf6ea51fd040948b715c0db196993936135c0ada1040d9f634362c6a56d7.

---

<a id="pubmed-pmid-39917770-elamipretide-v1"></a>

## Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.

> PubMed lists PMID 39917770 in European heart journal. Case reports as Case Reports, Journal Article, with publication-date metadata of 2025-01-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39917770-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-02-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39917770-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39917770-elamipretide-v1
- Content SHA-256: `bc2a6c4a0228e74c0b0369e6e740f4a6896b5fae1911e70ca8be9fba23c66714`

### Claims and source pins

#### Headline

Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. ([`pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69`](#source-pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69))

#### Summary

PubMed lists PMID 39917770 in European heart journal. Case reports as Case Reports, Journal Article, with publication-date metadata of 2025-01-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69`](#source-pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69))

#### Paragraph 1

PubMed lists PMID 39917770 in European heart journal. Case reports as Case Reports, Journal Article, with publication-date metadata of 2025-01-22 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69`](#source-pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69`](#source-pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69))

### Sources

<a id="source-pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69"></a>
- **Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. · retained source version 1:2025-02-08:current:0e4a75526b6907a2c248ce693486c9a41703e57251d2f13a41f16706b5f65d87** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39917770/) (`pubmed-observation-pmid-39917770-2025-02-08-0e4a75526b69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-39917770-elamipretide-v1 SHA-256: bc2a6c4a0228e74c0b0369e6e740f4a6896b5fae1911e70ca8be9fba23c66714.

---

<a id="pubmed-pmid-40570323-elamipretide-v1"></a>

## PubMed record PMID 40570323

> PeptideScanner retained PubMed bibliographic metadata for PMID 40570323 at 2026-07-30T16:14:11.030Z. PubMed recorded a metadata revision date of 2026-06-17 and an Entrez history date of 2025-06-26. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40570323-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40570323-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-40570323-elamipretide-v1
- Content SHA-256: `3b6ef921dedc5312bfe7ec00ce6d80ab037fc41cbc907d1f2c620d1281760012`

### Claims and source pins

#### Headline

PubMed record PMID 40570323 ([`pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95`](#source-pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40570323 at 2026-07-30T16:14:11.030Z. PubMed recorded a metadata revision date of 2026-06-17 and an Entrez history date of 2025-06-26. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95`](#source-pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40570323 at 2026-07-30T16:14:11.030Z. PubMed recorded a metadata revision date of 2026-06-17 and an Entrez history date of 2025-06-26. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95`](#source-pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95`](#source-pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95))

### Sources

<a id="source-pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95"></a>
- **PubMed record PMID 40570323 · retained source version 1:2026-06-17:current:d693c9679e95bad82e9509f5061156cf4a61466e59b4a3fa77b89ae51f4c0bf2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40570323/) (`pubmed-observation-pmid-40570323-2026-06-17-d693c9679e95`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40570323." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-40570323-elamipretide-v1 SHA-256: 3b6ef921dedc5312bfe7ec00ce6d80ab037fc41cbc907d1f2c620d1281760012.

---

<a id="pubmed-pmid-40816230-elamipretide-v1"></a>

## Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

> PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40816230-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-11-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40816230-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-40816230-elamipretide-v1
- Content SHA-256: `035dfde7397bb97b919e7dfeec1f9c5f95b183856699fa08a5b690473c51ae23`

### Claims and source pins

#### Headline

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

#### Summary

PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

#### Paragraph 1

PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

### Sources

<a id="source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d"></a>
- **Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report. · retained source version 1:2025-11-18:current:506865bd302d203673f4913d365ef6fe2adfbf85cbe80cf03e09b744cecfc857** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40816230/) (`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-40816230-elamipretide-v1 SHA-256: 035dfde7397bb97b919e7dfeec1f9c5f95b183856699fa08a5b690473c51ae23.

---

<a id="pubmed-pmid-41260682-elamipretide-v1"></a>

## Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

> PubMed lists PMID 41260682 in Drug discoveries & therapeutics as Letter, with publication-date metadata of 2025-11-20 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41260682-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41260682-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41260682-elamipretide-v1
- Content SHA-256: `133a85dfbbd84e2a3c8e7d134e523b3c00ae71832a078d8217b3727d2c44e380`

### Claims and source pins

#### Headline

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. ([`pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa`](#source-pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa))

#### Summary

PubMed lists PMID 41260682 in Drug discoveries & therapeutics as Letter, with publication-date metadata of 2025-11-20 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa`](#source-pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa))

#### Paragraph 1

PubMed lists PMID 41260682 in Drug discoveries & therapeutics as Letter, with publication-date metadata of 2025-11-20 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa`](#source-pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa`](#source-pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa))

### Sources

<a id="source-pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa"></a>
- **Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. · retained source version 1:2026-01-14:current:85a850a90afaf120fd282509822376f12f18ab63e6a893db5979cdc1097c8420** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41260682/) (`pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41260682-elamipretide-v1 SHA-256: 133a85dfbbd84e2a3c8e7d134e523b3c00ae71832a078d8217b3727d2c44e380.

---

<a id="pubmed-pmid-41500837-elamipretide-v1"></a>

## PubMed record PMID 41500837

> PeptideScanner retained PubMed bibliographic metadata for PMID 41500837 at 2026-07-30T16:14:13.067Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41500837-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41500837-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41500837-elamipretide-v1
- Content SHA-256: `2576c8e65203a3ef2111c99febb822016d39ee7f90aaa19a3e4cbddc25ea1887`

### Claims and source pins

#### Headline

PubMed record PMID 41500837 ([`pubmed-observation-pmid-41500837-2026-06-25-79f773486e10`](#source-pubmed-observation-pmid-41500837-2026-06-25-79f773486e10))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41500837 at 2026-07-30T16:14:13.067Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41500837-2026-06-25-79f773486e10`](#source-pubmed-observation-pmid-41500837-2026-06-25-79f773486e10))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41500837 at 2026-07-30T16:14:13.067Z. PubMed recorded a metadata revision date of 2026-06-25 and an Entrez history date of 2026-01-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41500837-2026-06-25-79f773486e10`](#source-pubmed-observation-pmid-41500837-2026-06-25-79f773486e10))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41500837-2026-06-25-79f773486e10`](#source-pubmed-observation-pmid-41500837-2026-06-25-79f773486e10))

### Sources

<a id="source-pubmed-observation-pmid-41500837-2026-06-25-79f773486e10"></a>
- **PubMed record PMID 41500837 · retained source version 1:2026-06-25:current:79f773486e10088782544536b8e3ebd9b2c9caa7b83112117457c06b241a38f0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41500837/) (`pubmed-observation-pmid-41500837-2026-06-25-79f773486e10`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41500837." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41500837-elamipretide-v1 SHA-256: 2576c8e65203a3ef2111c99febb822016d39ee7f90aaa19a3e4cbddc25ea1887.

---

<a id="pubmed-pmid-41596703-elamipretide-v1"></a>

## PubMed record PMID 41596703

> PeptideScanner retained PubMed bibliographic metadata for PMID 41596703 at 2026-07-30T16:11:44.884Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41596703-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41596703-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41596703-elamipretide-v1
- Content SHA-256: `d0a1bed2673de3a932ca2bea5a40d5b81e8874bbff74ae72bcb82c9c56141661`

### Claims and source pins

#### Headline

PubMed record PMID 41596703 ([`pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9`](#source-pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41596703 at 2026-07-30T16:11:44.884Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9`](#source-pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41596703 at 2026-07-30T16:11:44.884Z. PubMed recorded a metadata revision date of 2026-07-01 and an Entrez history date of 2026-01-28. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9`](#source-pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9`](#source-pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9))

### Sources

<a id="source-pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9"></a>
- **PubMed record PMID 41596703 · retained source version 1:2026-07-01:current:219a755d2be9bf28098e5d20c97158ebd1f8a47cfafbd6f8ecaab125c9178758** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41596703/) (`pubmed-observation-pmid-41596703-2026-07-01-219a755d2be9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41596703." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41596703-elamipretide-v1 SHA-256: d0a1bed2673de3a932ca2bea5a40d5b81e8874bbff74ae72bcb82c9c56141661.

---

<a id="pubmed-pmid-41612464-elamipretide-v1"></a>

## PubMed record PMID 41612464

> PeptideScanner retained PubMed bibliographic metadata for PMID 41612464 at 2026-07-30T16:14:14.832Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-01-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41612464-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41612464-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41612464-elamipretide-v1
- Content SHA-256: `8d04b129c629a23738f8370e7a0cdc9a6b1535e1aa74c5d70fe057cee903042f`

### Claims and source pins

#### Headline

PubMed record PMID 41612464 ([`pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3`](#source-pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41612464 at 2026-07-30T16:14:14.832Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-01-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3`](#source-pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41612464 at 2026-07-30T16:14:14.832Z. PubMed recorded a metadata revision date of 2026-06-27 and an Entrez history date of 2026-01-30. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3`](#source-pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3`](#source-pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3))

### Sources

<a id="source-pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3"></a>
- **PubMed record PMID 41612464 · retained source version 1:2026-06-27:current:281d1524a8d38da4581cd36e84b83133662645c27d762d9d59c14e55b5f431b4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41612464/) (`pubmed-observation-pmid-41612464-2026-06-27-281d1524a8d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41612464." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41612464-elamipretide-v1 SHA-256: 8d04b129c629a23738f8370e7a0cdc9a6b1535e1aa74c5d70fe057cee903042f.

---

<a id="pubmed-pmid-41801306-elamipretide-v1"></a>

## PubMed record PMID 41801306

> PeptideScanner retained PubMed bibliographic metadata for PMID 41801306 at 2026-08-10T18:13:44.801Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41801306-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-10
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41801306-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41801306-elamipretide-v1
- Content SHA-256: `b9a76271618a781845dc5b1d91b57218bd45093d09724e1f673f79344a9fd8cc`

### Claims and source pins

#### Headline

PubMed record PMID 41801306 ([`pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e`](#source-pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41801306 at 2026-08-10T18:13:44.801Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e`](#source-pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41801306 at 2026-08-10T18:13:44.801Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e`](#source-pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e`](#source-pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e))

### Sources

<a id="source-pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e"></a>
- **PubMed record PMID 41801306 · retained source version 1:2026-07-10:current:8b5ed316911e138acf8216a646f750ca2ae8ecaaa33c629de37e9f88a746cac1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41801306/) (`pubmed-observation-pmid-41801306-2026-07-10-8b5ed316911e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41801306." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-41801306-elamipretide-v1 SHA-256: b9a76271618a781845dc5b1d91b57218bd45093d09724e1f673f79344a9fd8cc.

---

<a id="pubmed-pmid-42082001-elamipretide-v1"></a>

## PubMed record PMID 42082001

> PeptideScanner retained PubMed bibliographic metadata for PMID 42082001 at 2026-07-30T16:14:16.712Z. PubMed recorded a metadata revision date of 2026-06-12 and an Entrez history date of 2026-05-04. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42082001-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42082001-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42082001-elamipretide-v1
- Content SHA-256: `738c6c328bc1661c37292f76e3384e30dcc46d46bbbc09061fa0f4771126e748`

### Claims and source pins

#### Headline

PubMed record PMID 42082001 ([`pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4`](#source-pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42082001 at 2026-07-30T16:14:16.712Z. PubMed recorded a metadata revision date of 2026-06-12 and an Entrez history date of 2026-05-04. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4`](#source-pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42082001 at 2026-07-30T16:14:16.712Z. PubMed recorded a metadata revision date of 2026-06-12 and an Entrez history date of 2026-05-04. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4`](#source-pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4`](#source-pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4))

### Sources

<a id="source-pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4"></a>
- **PubMed record PMID 42082001 · retained source version 1:2026-06-12:current:1c28fbb208e498d9ddb449f9dd8d8614a947eb0b39714f2f1e23f075b5f3bfdc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42082001/) (`pubmed-observation-pmid-42082001-2026-06-12-1c28fbb208e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42082001." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42082001-elamipretide-v1 SHA-256: 738c6c328bc1661c37292f76e3384e30dcc46d46bbbc09061fa0f4771126e748.

---

<a id="pubmed-pmid-42219795-elamipretide-v1"></a>

## PubMed record PMID 42219795

> PeptideScanner retained PubMed bibliographic metadata for PMID 42219795 at 2026-08-10T18:13:50.715Z. PubMed recorded a metadata revision date of 2026-07-17 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42219795-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-17
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42219795-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42219795-elamipretide-v1
- Content SHA-256: `1ee3489019f67f1dd596bf520f61f6463c0f1af51c59f35ac3a25bb487aee49f`

### Claims and source pins

#### Headline

PubMed record PMID 42219795 ([`pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24`](#source-pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42219795 at 2026-08-10T18:13:50.715Z. PubMed recorded a metadata revision date of 2026-07-17 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24`](#source-pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42219795 at 2026-08-10T18:13:50.715Z. PubMed recorded a metadata revision date of 2026-07-17 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24`](#source-pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24`](#source-pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24))

### Sources

<a id="source-pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24"></a>
- **PubMed record PMID 42219795 · retained source version 1:2026-07-17:current:e31ef5aa4b2408459dd497177a20c5b31896ca6cb92b8a7b5fc4c615bb610623** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42219795/) (`pubmed-observation-pmid-42219795-2026-07-17-e31ef5aa4b24`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42219795." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42219795-elamipretide-v1 SHA-256: 1ee3489019f67f1dd596bf520f61f6463c0f1af51c59f35ac3a25bb487aee49f.

---

<a id="pubmed-pmid-42290373-elamipretide-v1"></a>

## PubMed record PMID 42290373

> PeptideScanner retained PubMed bibliographic metadata for PMID 42290373 at 2026-07-30T16:14:18.165Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42290373-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42290373-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42290373-elamipretide-v1
- Content SHA-256: `2bd4c5b70a2e6f8077e6a6675ff7c5932e3eba35523af3636ce27ae309dc8c1f`

### Claims and source pins

#### Headline

PubMed record PMID 42290373 ([`pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44`](#source-pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42290373 at 2026-07-30T16:14:18.165Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44`](#source-pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42290373 at 2026-07-30T16:14:18.165Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44`](#source-pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44`](#source-pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44))

### Sources

<a id="source-pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44"></a>
- **PubMed record PMID 42290373 · retained source version 1:2026-06-15:current:029007bd7e44a828736aebc82f7bd13f6d257419035b6973441eedfba0610a5e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42290373/) (`pubmed-observation-pmid-42290373-2026-06-15-029007bd7e44`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42290373." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42290373-elamipretide-v1 SHA-256: 2bd4c5b70a2e6f8077e6a6675ff7c5932e3eba35523af3636ce27ae309dc8c1f.

---

<a id="pubmed-pmid-42291734-elamipretide-v1"></a>

## PubMed record PMID 42291734

> PeptideScanner retained PubMed bibliographic metadata for PMID 42291734 at 2026-07-30T16:14:19.224Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42291734-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42291734-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42291734-elamipretide-v1
- Content SHA-256: `6a663ea9656956871b2497755d53918ec836cb64e40497c0686d8738d2815ce9`

### Claims and source pins

#### Headline

PubMed record PMID 42291734 ([`pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b`](#source-pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42291734 at 2026-07-30T16:14:19.224Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b`](#source-pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42291734 at 2026-07-30T16:14:19.224Z. PubMed recorded a metadata revision date of 2026-06-15 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b`](#source-pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b`](#source-pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b))

### Sources

<a id="source-pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b"></a>
- **PubMed record PMID 42291734 · retained source version 1:2026-06-15:current:329ac0706c0bb72b4df352e74041939f471ebb1da4f0df395b6ff03775a33a0d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42291734/) (`pubmed-observation-pmid-42291734-2026-06-15-329ac0706c0b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42291734." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42291734-elamipretide-v1 SHA-256: 6a663ea9656956871b2497755d53918ec836cb64e40497c0686d8738d2815ce9.

---

<a id="pubmed-pmid-42415111-elamipretide-v1"></a>

## PubMed record PMID 42415111

> PeptideScanner retained PubMed bibliographic metadata for PMID 42415111 at 2026-08-10T18:13:53.859Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2026-07-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42415111-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42415111-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42415111-elamipretide-v1
- Content SHA-256: `8ae09892e45ca6e3ae0c1764af27a7d64cad6098da8b153a4cbd8cd7f2bb2cff`

### Claims and source pins

#### Headline

PubMed record PMID 42415111 ([`pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75`](#source-pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42415111 at 2026-08-10T18:13:53.859Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2026-07-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75`](#source-pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42415111 at 2026-08-10T18:13:53.859Z. PubMed recorded a metadata revision date of 2026-07-07 and an Entrez history date of 2026-07-07. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75`](#source-pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75`](#source-pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75))

### Sources

<a id="source-pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75"></a>
- **PubMed record PMID 42415111 · retained source version 1:2026-07-07:current:0a2366e0ed754f15a656f1bf459eb01c5bc52f74df180cf86f95663886fd144a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42415111/) (`pubmed-observation-pmid-42415111-2026-07-07-0a2366e0ed75`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42415111." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42415111-elamipretide-v1 SHA-256: 8ae09892e45ca6e3ae0c1764af27a7d64cad6098da8b153a4cbd8cd7f2bb2cff.

---

<a id="pubmed-pmid-42443448-elamipretide-v1"></a>

## PubMed record PMID 42443448

> PeptideScanner retained PubMed bibliographic metadata for PMID 42443448 at 2026-08-10T18:13:55.249Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42443448-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-13
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42443448-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42443448-elamipretide-v1
- Content SHA-256: `fc1866ae936309d86995104b757ffb883ddf57ec4e6291df147a3e7f1531fa48`

### Claims and source pins

#### Headline

PubMed record PMID 42443448 ([`pubmed-observation-pmid-42443448-2026-07-13-afac8deea530`](#source-pubmed-observation-pmid-42443448-2026-07-13-afac8deea530))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42443448 at 2026-08-10T18:13:55.249Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42443448-2026-07-13-afac8deea530`](#source-pubmed-observation-pmid-42443448-2026-07-13-afac8deea530))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42443448 at 2026-08-10T18:13:55.249Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42443448-2026-07-13-afac8deea530`](#source-pubmed-observation-pmid-42443448-2026-07-13-afac8deea530))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42443448-2026-07-13-afac8deea530`](#source-pubmed-observation-pmid-42443448-2026-07-13-afac8deea530))

### Sources

<a id="source-pubmed-observation-pmid-42443448-2026-07-13-afac8deea530"></a>
- **PubMed record PMID 42443448 · retained source version 1:2026-07-13:current:afac8deea530d4fccd2fd53122b3179c3defd71758be04614302ed7277a15d7e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42443448/) (`pubmed-observation-pmid-42443448-2026-07-13-afac8deea530`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42443448." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42443448-elamipretide-v1 SHA-256: fc1866ae936309d86995104b757ffb883ddf57ec4e6291df147a3e7f1531fa48.

---

<a id="pubmed-pmid-42448476-elamipretide-v1"></a>

## PubMed record PMID 42448476

> PeptideScanner retained PubMed bibliographic metadata for PMID 42448476 at 2026-08-10T18:13:55.255Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42448476-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-14
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42448476-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42448476-elamipretide-v1
- Content SHA-256: `2733030c2bde9c0706fa95ce0f0b2a2da16308643e9c6339b0e8f3301ddfb36c`

### Claims and source pins

#### Headline

PubMed record PMID 42448476 ([`pubmed-observation-pmid-42448476-2026-07-14-0416f687502e`](#source-pubmed-observation-pmid-42448476-2026-07-14-0416f687502e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42448476 at 2026-08-10T18:13:55.255Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42448476-2026-07-14-0416f687502e`](#source-pubmed-observation-pmid-42448476-2026-07-14-0416f687502e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42448476 at 2026-08-10T18:13:55.255Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42448476-2026-07-14-0416f687502e`](#source-pubmed-observation-pmid-42448476-2026-07-14-0416f687502e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42448476-2026-07-14-0416f687502e`](#source-pubmed-observation-pmid-42448476-2026-07-14-0416f687502e))

### Sources

<a id="source-pubmed-observation-pmid-42448476-2026-07-14-0416f687502e"></a>
- **PubMed record PMID 42448476 · retained source version 1:2026-07-14:current:0416f687502e6c432a25ca9e16bde5955e4737939725a6ffa7d029ead9b35ed6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42448476/) (`pubmed-observation-pmid-42448476-2026-07-14-0416f687502e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42448476." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42448476-elamipretide-v1 SHA-256: 2733030c2bde9c0706fa95ce0f0b2a2da16308643e9c6339b0e8f3301ddfb36c.

---

<a id="pubmed-pmid-42450582-elamipretide-v1"></a>

## PubMed record PMID 42450582

> PeptideScanner retained PubMed bibliographic metadata for PMID 42450582 at 2026-08-10T18:13:55.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42450582-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42450582-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42450582-elamipretide-v1
- Content SHA-256: `dcf3d6aaf30b921f1c52e2a9073c38a4c9cf41e6cc234c5d6750c87a8a41d957`

### Claims and source pins

#### Headline

PubMed record PMID 42450582 ([`pubmed-observation-pmid-42450582-2026-07-26-518454187e30`](#source-pubmed-observation-pmid-42450582-2026-07-26-518454187e30))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42450582 at 2026-08-10T18:13:55.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42450582-2026-07-26-518454187e30`](#source-pubmed-observation-pmid-42450582-2026-07-26-518454187e30))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42450582 at 2026-08-10T18:13:55.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42450582-2026-07-26-518454187e30`](#source-pubmed-observation-pmid-42450582-2026-07-26-518454187e30))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42450582-2026-07-26-518454187e30`](#source-pubmed-observation-pmid-42450582-2026-07-26-518454187e30))

### Sources

<a id="source-pubmed-observation-pmid-42450582-2026-07-26-518454187e30"></a>
- **PubMed record PMID 42450582 · retained source version 1:2026-07-26:current:518454187e3080a7722ceb7eddfc33e4ea774a6821cc37879a8f3280ffa5ded5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42450582/) (`pubmed-observation-pmid-42450582-2026-07-26-518454187e30`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42450582." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42450582-elamipretide-v1 SHA-256: dcf3d6aaf30b921f1c52e2a9073c38a4c9cf41e6cc234c5d6750c87a8a41d957.

---

<a id="pubmed-pmid-42456009-elamipretide-v1"></a>

## PubMed record PMID 42456009

> PeptideScanner retained PubMed bibliographic metadata for PMID 42456009 at 2026-08-10T18:13:55.284Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42456009-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42456009-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42456009-elamipretide-v1
- Content SHA-256: `f0090a896205af25685018f71dcbd36b9ec6f10b6e6869d1d35d88512e917215`

### Claims and source pins

#### Headline

PubMed record PMID 42456009 ([`pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef`](#source-pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42456009 at 2026-08-10T18:13:55.284Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef`](#source-pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42456009 at 2026-08-10T18:13:55.284Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef`](#source-pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef`](#source-pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef))

### Sources

<a id="source-pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef"></a>
- **PubMed record PMID 42456009 · retained source version 1:2026-07-27:current:a62f8537e4eff71b2ef3f16e89333c4546df562d6f17119e16b79b1a56bb5058** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42456009/) (`pubmed-observation-pmid-42456009-2026-07-27-a62f8537e4ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42456009." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42456009-elamipretide-v1 SHA-256: f0090a896205af25685018f71dcbd36b9ec6f10b6e6869d1d35d88512e917215.

---

<a id="pubmed-pmid-42708867-elamipretide-v1"></a>

## Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.

> PubMed lists PMID 42708867 in Physiological research as Journal Article, Comparative Study, with publication-date metadata of 2026-08-31 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42708867-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-08
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42708867-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42708867-elamipretide-v1
- Content SHA-256: `fd0dcb975552f0bc0d43a40f0404f846ea8431cc36a90e11607419567cc43990`

### Claims and source pins

#### Headline

Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress. ([`pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58`](#source-pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58))

#### Summary

PubMed lists PMID 42708867 in Physiological research as Journal Article, Comparative Study, with publication-date metadata of 2026-08-31 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58`](#source-pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58))

#### Paragraph 1

PubMed lists PMID 42708867 in Physiological research as Journal Article, Comparative Study, with publication-date metadata of 2026-08-31 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58`](#source-pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58`](#source-pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58))

### Sources

<a id="source-pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58"></a>
- **Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress. · retained source version 1:2026-09-08:current:9c22a430cf58fa20690de0975c3a3f218033d7441e568837258b455c1c24d378** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42708867/) (`pubmed-observation-pmid-42708867-2026-09-08-9c22a430cf58`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/elamipretide.json#pubmed-pmid-42708867-elamipretide-v1 SHA-256: fd0dcb975552f0bc0d43a40f0404f846ea8431cc36a90e11607419567cc43990.

